Evaxion Biotech A/S Statistics Share Statistics Evaxion Biotech A/S has 6.32M
shares outstanding. The number of shares has increased by -11.04%
in one year.
Shares Outstanding 6.32M Shares Change (YoY) -11.04% Shares Change (QoQ) -11.18% Owned by Institutions (%) 15.81% Shares Floating 5.1M Failed to Deliver (FTD) Shares 212 FTD / Avg. Volume 0.2%
Short Selling Information The latest short interest is 125.16K, so 1.98% of the outstanding
shares have been sold short.
Short Interest 125.16K Short % of Shares Out 1.98% Short % of Float 2.65% Short Ratio (days to cover) 2.17
Valuation Ratios The PE ratio is -0.43 and the forward
PE ratio is -2.15.
Evaxion Biotech A/S's PEG ratio is
0.01.
PE Ratio -0.43 Forward PE -2.15 PS Ratio 1.36 Forward PS 4.2 PB Ratio -2.75 P/FCF Ratio -0.35 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Evaxion Biotech A/S.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.01,
with a Debt / Equity ratio of -6.11.
Current Ratio 2.01 Quick Ratio 2.01 Debt / Equity -6.11 Debt / EBITDA -1.03 Debt / FCF -0.78 Interest Coverage -15.31
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $72.7K Profits Per Employee $-229.72K Employee Count 46 Asset Turnover 0.27 Inventory Turnover n/a
Taxes Income Tax -788K Effective Tax Rate 6.94%
Stock Price Statistics The stock price has increased by -83.07% in the
last 52 weeks. The beta is 0.14, so Evaxion Biotech A/S's
price volatility has been higher than the market average.
Beta 0.14 52-Week Price Change -83.07% 50-Day Moving Average 2.76 200-Day Moving Average 3.05 Relative Strength Index (RSI) 51.66 Average Volume (20 Days) 106,879
Income Statement In the last 12 months, Evaxion Biotech A/S had revenue of 3.34M
and earned -10.57M
in profits. Earnings per share was -9.8.
Revenue 3.34M Gross Profit 3.34M Operating Income -14.73M Net Income -10.57M EBITDA -9.77M EBIT -10.39M Earnings Per Share (EPS) -9.8
Full Income Statement Balance Sheet The company has 5.05M in cash and 10.1M in
debt, giving a net cash position of -5.05M.
Cash & Cash Equivalents 5.05M Total Debt 10.1M Net Cash -5.05M Retained Earnings -118.54M Total Assets 22.45M Working Capital 12.86M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -12.94M
and capital expenditures 4.69, giving a free cash flow of -12.94M.
Operating Cash Flow -12.94M Capital Expenditures 4.69 Free Cash Flow -12.94M FCF Per Share -12.06
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -440.55% and -316%.
Gross Margin 100% Operating Margin -440.55% Pretax Margin -339.56% Profit Margin -316% EBITDA Margin -292.14% EBIT Margin -440.55% FCF Margin -386.96%
Dividends & Yields EVAX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for EVAX is $10,
which is 242.5% higher than the current price. The consensus rating is "Buy".
Price Target $10 Price Target Difference 242.5% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 14, 2025. It was a
backward
split with a ratio of 1:5.
Last Split Date Jan 14, 2025 Split Type backward Split Ratio 1:5
Scores Altman Z-Score -8.3 Piotroski F-Score 3
